Median progression-free survival ( PFS ) and overall survival ( OS ) were 5.8 months ( 95 % confidence interval [ CI ] : 5.3-6 .5 ) and 10.5 months ( 8.9-13 .8 ) with CbEOb and 5.2 months ( 95 % CI : 4.1-5 .7 ) and 9.8 months ( 7.2-11 .2 ) with CbE .